Abstract:BackgroundOne of the mechanisms by which tumors evade immune surveillance is through shedding of the major histocompatibility complex (MHC) class I chain-related protein A and B (MICA/B) from their cell surface. MICA/B are ligands for the activating receptor NKG2D on NK and CD8 T cells. This shedding reduces cell surface levels of MICA/B and impairs NKG2D recognition. Shed MICA/B can also mask NKG2D receptor and is thought to induce NKG2D internalization, further compromising immune surveillance by NK cells.MethodsWe isolated human primary NK cells from normal donors and tested the suppressive activity of soluble recombinant MICA in vitro. Utilizing a panel of novel anti-MICA antibodies, we further examined the stimulatory activities of anti-MICA antibodies that reversed the suppressive effects of soluble MICA.ResultsWe show that suppressive effects of soluble MICA (sMICA) on NK cell cytolytic activity was not due to the down-regulation of cell surface NKG2D. In the presence of an α3 domain-specific MICA antibody, which did not obstruct NKG2D binding, sMICA-mediated NK cell suppression was completely reversed. Reversal of NK cell inhibition by sMICA was mediated by immune complex formation that agonized NKG2D signaling. Furthermore, this restorative activity was dependent on antibody Fc effector function as the introduction of Fc mutations to abrogate Fc receptor binding failed to reverse sMICA-mediated NK cell suppression. Furthermore, MICA immune complexes preformed with an α3 domain-specific antibody (containing a wild-type Fc) induced IFN-γ and TNF-α secretion by NK cells in the absence of cancer cells, whereas MICA immune complexes preformed with the Fc effectorless antibody failed to induce IFN-γ and TNF-α secretion. Finally, we demonstrated that MICA immune complexes formed with the α3 domain-specific antibody activates NKG2D on NK cells leading to the release of IFN-γ.ConclusionsOur results demonstrate that an α3 domain-specific MICA antibody can circumvent sMICA-mediated suppression of NK cell cytolytic activity. Moreover, our data suggest that MICA immune complexes formed with α3-specific antibodies can activate NKG2D receptor and restore NK cell function in a Fc-dependent manner. The clinical utility of α3 domain-specific MICA/B antibodies may hold great promise as a new strategy for cancer immunotherapy.

Interactions of Human Nkg2d with Its Ligands Mica, Micb, and Homologs of the Mouse Rae-1 Protein Family

Complex Structure of the Activating Immunoreceptor NKG2D and Its MHC Class I–like Ligand MICA

UL16 binding proteins.

The Inhibitory Effects of Synthetic Short Peptides, Mimicking MICA and Targeting at NKG2D Receptors, on Function of NK Cells

Multiple Mechanisms Downstream of TLR-4 Stimulation Allow Expression of NKG2D Ligands To Facilitate Macrophage/NK Cell Crosstalk

Expression and function of the major histocompatibility complex (MHC) class I chain-related A (MICA)*010 in NK cell killing activity

Structural Studies of Allelic Diversity of the MHC Class I Homolog MIC-B, a Stress-Inducible Ligand for the Activating Immunoreceptor NKG2D

Impact of the MICA-129Met/Val Dimorphism on NKG2D-Mediated Biological Functions and Disease Risks

The MICA-129Met/Val dimorphism affects plasma membrane expression and shedding of the NKG2D ligand MICA

Expression and Significance of NKG2D Ligands in 13 Tumor Cell Lines

The Opposite Effect of Mmica and Rmica on the Expression of NKG2D and the Influence on NK Cell Receptor Repertoire

Modulation of Singnaling Preference of Nk Cells by Different Forms of Nkg2d Ligands and Its Implications

MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner

Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation

Structure of the murine CD94–NKG2A receptor in complex with Qa‐1b presenting an MHC‐I leader peptide

Crystal Structures Of Rae-1 Beta And Its Complex With The Activating Immunoreceptor Nkg2d

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

Contact Inhibition Causes Strong Downregulation of Expression of MICA in Human Fibroblasts and Decreased NK Cell Killing

NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain

CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence

NKG2D and MICA/B shedding: a ‘tag game’ between NK cells and malignant cells